WHAT IS CLAIMED IS:

1. A method for treating excessive osteolysis in a patient, comprising administering to said patient an effective amount of a compound of Formula I:



(I),

wherein

R is independently H, OH, alkyl, aryl, cycloalkyl, heteroaryl, alkoxy, heterocyclic and amino;

each R_1 is independently selected from the group consisting of alkyl, halo, aryl, alkoxy, haloalkyl, haloalkoxy, cycloalkyl, heteroaryl, heterocyclic, hydroxy, $-C(O)-R_8$, $-NR_9R_{10}$, $-NR_9C(O)-R_{12}$ and $-C(O)NR_9R_{10}$;

each R_2 is independently selected from the group consisting of alkyl, aryl, heteroaryl, $-C(O)-R_8$ and SO_2R'', where R'' is alkyl, aryl, heteroaryl, NR_9N_{10} or alkoxy;

each R_5 is independently selected from the group consisting of hydrogen, alkyl, aryl, haloalkyl, cycloalkyl, heteroaryl, heterocyclic, hydroxy, $-C(O)-R_8$ and $(CHR)_rR_{11}$;

X is O or S;

p is 0-3;

q is 0-2;

r is 0-3;

R_8 is selected from the group consisting of –OH, alkyl, aryl, heteroaryl, alkoxy, cycloalkyl and heterocyclic;

R_9 and R_{10} are independently selected from the group consisting of H, alkyl, aryl, aminoalkyl, heteroaryl, cycloalkyl and heterocyclic, or R_9 and R_{10} together with N may form a ring, where the ring atoms are selected from the group consisting of C, N, O and S;

R_{11} is selected from the group consisting of –OH, amino, monosubstituted amino, disubstituted amino, alkyl, aryl, heteroaryl, alkoxy, cycloalkyl and heterocyclic;

R_{12} is selected from the group consisting of alkyl, aryl, heteroaryl, alkoxy, cycloalkyl and heterocyclic;

Z is OH, O-alkyl, or $-NR_3R_4$, where R_3 and R_4 are independently selected from the group consisting of hydrogen, alkyl, aryl, heteroaryl, cycloalkyl, and heterocyclic, or R_3 and R_4 may combine with N to form a ring where the ring atoms are selected from the group consisting of CH_2, N, O and S or



wherein Y is independently CH_2, O, N or S,

Q is C or N;

n is independently 0-4; and

m is 0-3;

or a salt thereof.

2. The method of claim 1, wherein R_1 is halo and p is 1.

3. The method of claim 2, where Z is $-NR_3R_4$, wherein R_3 and R_4 form a morpholine ring.

4. The method of claim 1, wherein Z is:



wherein each Y is CH_2, each n is 2, m is 0 and R_3 and R_4 form a morpholine ring.

5. The method of any of claims 1-3, wherein R_2 is methyl and q is 2, wherein the methyls are bonded at the 3 and 5 positions.

6. The method of claim 1, wherein the compound administered is a compound of Formula II:



(II).

7. The method of claim 6, wherein R_5 is H.

8. The method of claim 6, wherein R_2 is methyl, q is 2, wherein the methyls are bonded at the 3 and 5 positions.

9. The method of claim 6, wherein the patient has cancer that has metastasized to bone.

10. The method of claim 6, wherein the patient has a cancer that secretes M-CSF.

11. The method of claim 6, wherein the patient has osteoporosis.

12. The method of claim 6, wherein the patient is post-menopausal.

13. The method of claim 1, wherein the compound administered is selected from the group consisting of



,



,



,



and



14. The method of claim 1, wherein the compound of formula I is selected from the group consisting of:



Compound 1



Compound 2



Compound 3



Compound 8



Compound 6



Compound 7



Compound 4



Compound 9

and



Compound 5

15. A method of inhibiting phosphorylation of CSF1R in a patient in need of such inhibition, comprising administering to said patient an inhibitory amount of a compound of Formula I:



(I)

wherein

R is independently H, OH, alkyl, aryl, cycloalkyl, heteroaryl, alkoxy, heterocyclic and amino;

each R_1 is independently selected from the group consisting of alkyl, halo, aryl, alkoxy, haloalkyl, haloalkoxy, cycloalkyl, heteroaryl, heterocyclic, hydroxy, -C(O)-R_8, -NR_9R_{10}, -$NR_9C(O)$-R_{12} and –$C(O)NR_9R_{10}$;

each R_2 is independently selected from the group consisting of alkyl, aryl, heteroaryl, –C(O)-R_8 and SO_2R'', where R'' is alkyl, aryl, heteroaryl, NR_9N_{10} or alkoxy;

each R_5 is independently selected from the group consisting of hydrogen, alkyl, aryl, haloalkyl, cycloalkyl, heteroaryl, heterocyclic, hydroxy, -C(O)-R_8 and $(CHR)_rR_{11}$;

X is O or S;

p is 0-3;

q is 0-2;

r is 0-3;

R_8 is selected from the group consisting of –OH, alkyl, aryl, heteroaryl, alkoxy, cycloalkyl and heterocyclic;

R_9 and R_{10} are independently selected from the group consisting of H, alkyl, aryl, aminoalkyl, heteroaryl, cycloalkyl and heterocyclic, or R_9 and R_{10} together with N may form a ring, where the ring atoms are selected from the group consisting of C, N, O and S;

R_{11} is selected from the group consisting of –OH, amino, monosubstituted amino,

disubstituted amino, alkyl, aryl, heteroaryl, alkoxy, cycloalkyl and heterocyclic

R_{12} is selected from the group consisting of alkyl, aryl, heteroaryl, alkoxy, cycloalkyl and heterocyclic;

Z is OH, O-alkyl, or $-NR_3R_4$, where R_3 and R_4 are independently selected from the group consisting of hydrogen, alkyl, aryl, heteroaryl, cycloalkyl, and heterocyclic, or R_3 and R_4 may combine with N to form a ring where the ring atoms are selected from the group consisting of CH_2, N, O and S or



wherein Y is independently CH_2, O, N or S,

Q is C or N

n is independently 0-4; and

m is 0-3.